• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    DiaMedica Therapeutics Announces the Appointment of Biopharma Veteran Tanya Lewis to Its Board of Directors

    3/6/23 8:30:00 AM ET
    $DMAC
    $KPTI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $DMAC alert in real time by email

    DiaMedica Continues Building Out Board Of Directors With Key Biopharma Industry Leaders

    DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, announced today the appointment of Tanya Lewis to its board of directors effective March 1, 2023. Ms. Lewis, a recognized leader in the biopharma industry, brings over 25 years of experience in drug development, having played a key role in the approval of multiple new drugs.

    Ms. Lewis currently serves as the Chief Development Operations Officer at Replimune Group, Inc. where she has oversight for development of an integrated clinical, regulatory and CMC strategy for the successful registration of the company's compounds. Ms. Lewis joined the executive management team at Replimune in May 2021 after serving on Replimune's board of directors since November 2020.

    Prior to her officer position with Replimune, Tanya was Executive Vice President, Chief Regulatory Strategy and Strategic Operations at Karyopharm Therapeutics Inc., a publicly traded biopharmaceutical company (NASDAQ:KPTI), where she navigated the approval of XPOVIO®. Prior to joining Karyopharm, Ms. Lewis held leadership positions at several companies, including Tesaro and Millennium Pharmaceuticals, where she developed approval strategies and led interactions with U.S. and European regulators for registration trial designs and approvals. Ms. Lewis started her career at Genzyme Corporation in regulatory affairs. Ms. Lewis's past accomplishments include the successful negotiations for registration trial designs, approval, and/or commercialization of VELCADE®, VARUBI®, INTEGRILIN® and ZEJULA®.

    "Tanya is a respected and highly accomplished pharmaceutical industry executive with experience in global drug development and regulatory affairs. We're very excited to have Tanya join our board of directors at this critical time as we work to resolve the clinical hold on our ReMEDy2 AIS trial," commented Rich Pilnik, DiaMedica's Board Chairman.

    Ms. Lewis commented, "DiaMedica is at an exciting moment in its evolution and I look forward to working with the board of directors and management team to help the company on its mission to bring DM199 to benefit the millions of stroke patients without a treatment option today."

    Ms. Lewis holds a Bachelor of Science degree in Biology from Northeastern University and a Master of Science degree in Regulatory Affairs and Health Policy from Massachusetts College of Pharmacy and Allied Health Sciences.

    About DiaMedica Therapeutics Inc.

    DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from serious diseases. DiaMedica's lead candidate DM199 is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality for the treatment of acute ischemic stroke and chronic kidney disease. For more information visit the Company's website at www.diamedica.com.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20230306005174/en/

    Get the next $DMAC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $DMAC
    $KPTI

    CompanyDatePrice TargetRatingAnalyst
    DiaMedica Therapeutics Inc.
    $DMAC
    10/7/2024$7.00Buy
    H.C. Wainwright
    DiaMedica Therapeutics Inc.
    $DMAC
    4/24/2024$8.00Buy
    Craig Hallum
    DiaMedica Therapeutics Inc.
    $DMAC
    6/22/2023$7.00Perform → Outperform
    Oppenheimer
    Karyopharm Therapeutics Inc.
    $KPTI
    1/19/2023$8.00Overweight
    Piper Sandler
    Karyopharm Therapeutics Inc.
    $KPTI
    11/4/2022$7.00 → $10.00Sector Perform → Outperform
    RBC Capital Mkts
    Karyopharm Therapeutics Inc.
    $KPTI
    3/8/2022$12.00 → $8.00Sector Perform
    RBC Capital
    Karyopharm Therapeutics Inc.
    $KPTI
    3/2/2022$8.00 → $6.00Market Perform
    SVB Leerink
    Karyopharm Therapeutics Inc.
    $KPTI
    2/9/2022$8.00Underweight → Neutral
    JP Morgan
    More analyst ratings

    $DMAC
    $KPTI
    SEC Filings

    See more
    • SEC Form DEFA14A filed by Karyopharm Therapeutics Inc.

      DEFA14A - Karyopharm Therapeutics Inc. (0001503802) (Filer)

      4/14/25 8:19:11 AM ET
      $KPTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Karyopharm Therapeutics Inc.

      DEF 14A - Karyopharm Therapeutics Inc. (0001503802) (Filer)

      4/14/25 8:15:19 AM ET
      $KPTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by DiaMedica Therapeutics Inc.

      DEFA14A - DiaMedica Therapeutics Inc. (0001401040) (Filer)

      3/28/25 7:15:59 AM ET
      $DMAC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DMAC
    $KPTI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright initiated coverage on DiaMedica Therapeutics with a new price target

      H.C. Wainwright initiated coverage of DiaMedica Therapeutics with a rating of Buy and set a new price target of $7.00

      10/7/24 7:50:42 AM ET
      $DMAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Craig Hallum resumed coverage on DiaMedica Therapeutics with a new price target

      Craig Hallum resumed coverage of DiaMedica Therapeutics with a rating of Buy and set a new price target of $8.00

      4/24/24 8:38:29 AM ET
      $DMAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • DiaMedica Therapeutics upgraded by Oppenheimer with a new price target

      Oppenheimer upgraded DiaMedica Therapeutics from Perform to Outperform and set a new price target of $7.00

      6/22/23 7:34:26 AM ET
      $DMAC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DMAC
    $KPTI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President and CEO Paulson Richard A. sold $1,680 worth of shares (236 units at $7.12), decreasing direct ownership by 0.29% to 82,503 units (SEC Form 4)

      4 - Karyopharm Therapeutics Inc. (0001503802) (Issuer)

      5/7/25 5:03:41 PM ET
      $KPTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EVP & Chief Medical Officer Rangwala Reshma sold $2,585 worth of shares (419 units at $6.17), decreasing direct ownership by 1% to 28,853 units (SEC Form 4)

      4 - Karyopharm Therapeutics Inc. (0001503802) (Issuer)

      4/24/25 4:40:51 PM ET
      $KPTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Pilnik Richard D. exercised 24,000 units of Voting Common Shares at a strike of $2.11, increasing direct ownership by 8% to 312,995 units (SEC Form 4)

      4 - DiaMedica Therapeutics Inc. (0001401040) (Issuer)

      4/8/25 4:41:36 PM ET
      $DMAC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DMAC
    $KPTI
    Financials

    Live finance-specific insights

    See more
    • Karyopharm to Report First Quarter 2025 Financial Results on May 12, 2025

      -- Conference Call Scheduled for Monday, May 12, 2025, at 4:30 p.m. ET -- NEWTON, Mass., May 8, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it will report first quarter 2025 financial results on Monday, May 12, 2025. Karyopharm's management team will host a conference call and audio webcast at 4:30 p.m. ET on Monday, May 12, 2025, to discuss the financial results and other company updates. To access the conference call, please dial (800) 836-8184 (local) or (646) 357-8785 (international) at least 10 minutes prior to the start time and ask to be joined into the Karyopharm Therapeu

      5/8/25 4:05:00 PM ET
      $KPTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • DiaMedica Therapeutics to Report First Quarter 2025 Financial Results and Provide a Business Update May 14, 2025

      DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia and acute ischemic stroke, announced today that its first quarter 2025 financial results will be released after the markets close on Tuesday, May 13th. DiaMedica will host a live conference call on Wednesday, May 14th at 7:00 AM Central Time to provide a business update and discuss financial results. Conference Call details: Date: Wednesday, May 14, 2025 Time: 8:00 AM ET / 7:00 AM CT Web access: https://app.webinar.net/24NpV0mjklG Dial In: (800) 836-8184 Conference ID: 93262 Interested parties may access the

      5/7/25 8:30:00 AM ET
      $DMAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2024 Financial Results

      Conference Call and Webcast March 18 at 8:00 AM Eastern Time / 7:00 AM Central Time  Preeclampsia Phase 2 Trial Preliminary Topline Safety and Efficacy Data from Part 1A of the Study Expected in the Second Quarter of 2025 Acute Ischemic Stroke Phase 2/3 Program Enrollment Ongoing Appointed Experienced Biotech Executive Daniel J. O'Connor to the Board Cash Runway into Q3 2026 DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for acute ischemic stroke and preeclampsia, today provided a business update and financial results for the year ended December 31, 2024. Management will host a conference call Tuesday, M

      3/17/25 4:30:00 PM ET
      $DMAC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DMAC
    $KPTI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Karyopharm to Report First Quarter 2025 Financial Results on May 12, 2025

      -- Conference Call Scheduled for Monday, May 12, 2025, at 4:30 p.m. ET -- NEWTON, Mass., May 8, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it will report first quarter 2025 financial results on Monday, May 12, 2025. Karyopharm's management team will host a conference call and audio webcast at 4:30 p.m. ET on Monday, May 12, 2025, to discuss the financial results and other company updates. To access the conference call, please dial (800) 836-8184 (local) or (646) 357-8785 (international) at least 10 minutes prior to the start time and ask to be joined into the Karyopharm Therapeu

      5/8/25 4:05:00 PM ET
      $KPTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • DiaMedica Therapeutics to Participate in Upcoming Investor Conferences in May

      DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, announced today that the Company will participate in upcoming investor conferences in May 2025. 2025 RBC Capital Markets Global Healthcare Conference Tuesday, May 20th – Wednesday, May 21st, 2025, in New York City, New York. Management will be available for one-on-one meetings throughout the conference. H.C. Wainwright 3rd Annual BioConnect Conference Tuesday, May 20th, 2025, in New York City, New York. Management will participate in a fireside chat at 3:30 PM ET, which will be available via webcast at https://journey.ct.events/view/cb8

      5/8/25 4:00:00 PM ET
      $DMAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • DiaMedica Therapeutics to Report First Quarter 2025 Financial Results and Provide a Business Update May 14, 2025

      DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia and acute ischemic stroke, announced today that its first quarter 2025 financial results will be released after the markets close on Tuesday, May 13th. DiaMedica will host a live conference call on Wednesday, May 14th at 7:00 AM Central Time to provide a business update and discuss financial results. Conference Call details: Date: Wednesday, May 14, 2025 Time: 8:00 AM ET / 7:00 AM CT Web access: https://app.webinar.net/24NpV0mjklG Dial In: (800) 836-8184 Conference ID: 93262 Interested parties may access the

      5/7/25 8:30:00 AM ET
      $DMAC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DMAC
    $KPTI
    Leadership Updates

    Live Leadership Updates

    See more
    • DiaMedica Therapeutics Appoints Daniel J. O'Connor to the Board of Directors

      DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on acute ischemic stroke and preeclampsia, today announced the election of Daniel J. O'Connor to its Board of Directors, effective February 20, 2025. Mr. O'Connor has decades of executive experience and leadership in the biopharmaceutical industry, including as CEO and other executive level leadership positions at Ambrx Biopharma, Inc. (Ambrx), ImClone Systems Incorporated, Bracco Diagnostics, and PharmaNet (today, Syneos Health). Mr. O'Connor has gained a reputation as a seasoned and successful biopharma CEO, most recently serving as President, Chief Executive Officer and Director of Ambrx, wher

      2/24/25 8:30:00 AM ET
      $DMAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Karyopharm Announces the Appointment of Lori Macomber as Chief Financial Officer

      NEWTON, Mass., Jan. 2, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the appointment of Lori Macomber as Executive Vice President, Chief Financial Officer and Treasurer, effective January 3, 2025. In this role, Ms. Macomber will be responsible for leading and directing the financial activities of the Company. "Lori is an outstanding addition to the Karyopharm team," said Richard Paulson, President and Chief Executive Officer of Karyopharm. "She brings extensive experience in strategic financial management and operations, which will be critical as we execute on our strategy to grow

      1/2/25 7:00:00 AM ET
      $KPTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Karyopharm Announces the Appointment of Brendan Strong as Senior Vice President of Investor Relations and Corporate Communications

      NEWTON, Mass., Dec. 9, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the appointment of Brendan Strong as Senior Vice President of Investor Relations and Corporate Communications. "We are thrilled to have Brendan on board as we work towards delivering on and communicating important milestones for our organization in 2025," said Richard Paulson, President and Chief Executive Officer of Karyopharm. "Brendan's experience as a former sell-side analyst, advisor to biopharmaceutical companies and proven ability to develop strong investor relations and corporate communications programs wi

      12/9/24 8:00:00 AM ET
      $KPTI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DMAC
    $KPTI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Von Koch Thomas bought $3,000,000 worth of shares (1,200,000 units at $2.50) (SEC Form 4)

      4 - DiaMedica Therapeutics Inc. (0001401040) (Issuer)

      7/1/24 4:27:16 PM ET
      $DMAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Stahlberg Jan bought $3,000,000 worth of shares (1,200,000 units at $2.50) (SEC Form 4)

      4 - DiaMedica Therapeutics Inc. (0001401040) (Issuer)

      7/1/24 4:24:38 PM ET
      $DMAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wambeke David J. bought $49,200 worth of Voting Common Shares (20,000 units at $2.46), increasing direct ownership by 4% to 527,114 units (SEC Form 4)

      4 - DiaMedica Therapeutics Inc. (0001401040) (Issuer)

      11/16/23 4:37:28 PM ET
      $DMAC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DMAC
    $KPTI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Karyopharm Therapeutics Inc.

      SC 13G/A - Karyopharm Therapeutics Inc. (0001503802) (Subject)

      11/14/24 4:22:08 PM ET
      $KPTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Karyopharm Therapeutics Inc.

      SC 13G/A - Karyopharm Therapeutics Inc. (0001503802) (Subject)

      11/12/24 3:50:51 PM ET
      $KPTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Karyopharm Therapeutics Inc.

      SC 13G/A - Karyopharm Therapeutics Inc. (0001503802) (Subject)

      11/4/24 11:49:19 AM ET
      $KPTI
      Biotechnology: Pharmaceutical Preparations
      Health Care